Introduction
A defect in DNA mismatch repair (MMR) leads to the accumulation of mismatches, insertions and deletions in repeated sequences-a phenomenon named microsatellite instability (MSI). Approximately 20-30% of sporadic endometrial cancers (ECs) display MSI as a consequence of somatic promoter hypermethylation and silencing of MLH1 [1] . Defective MMR due to pathogenic germline variants in MMR genes causes Lynch syndrome (LS), a tumor predisposition syndrome that accounts for 2% of ECs [2] .
Determination of MMR-deficiency in EC may be important for several reasons. First, recent studies have suggested that tumor molecular features, including MMR-deficiency, may improve prognostication and help guide adjuvant therapy for EC patients [3, 4] . Second, accurate assessment of MMR-deficiency is essential to identify patients with EC caused by LS. However in contrast to colorectal cancer, where consensus guidelines for MMRdeficiency testing have been published [5] , there is no general agreement on screening EC patients for LS [6, 7] . Finally, recent studies have shown that MMR-deficiency in colorectal and urothelial cancer is predictive of response to immunotherapy [8, 9] , suggesting that MMR-deficient ECs may also benefit from these therapeutics.
MMR-deficiency can be detected by either MSI analysis and/or immunohistochemical (IHC) staining, typically for four MMR proteins. The National Cancer Institute microsatellite panel was optimized and correlated with IHC analysis (95%) to detect MMR-deficiency in colorectal cancer [10, 11] . IHC alone has become standard practice in multiple institutions. Experience in this setting is that while some tumors show uniform and widespread loss of MMR protein expression, cases with subclonal loss of MMR protein expression are also observed [11, 12] . Such cases present with two populations of tumor cells; one with retained expression, and another with abrupt and complete regional loss of MMR protein expression [12] . Small studies have shown high agreement between MSI and loss of MMR protein expression in EC [13] [14] [15] , while others have described subclonal loss of MMR protein expression [16] [17] [18] [19] [20] . However, studies identifying the frequency of such staining patterns in large patient series are sparse.
In this study, we sought to establish the optimum method for MMR-deficiency testing by comparison of MSI with IHC analysis in a large series of ECs. We also investigated the frequency of subclonal loss of MMR protein expression and the number of potential LS cases. Cases showing disagreement between methodologies and those with subclonal loss of MMR protein expression were further characterized.
Methods

Study population
The population comprised, 854 ECs from the PORTEC-1 and -2 clinical trials based on availability of formalin-fixed paraffin-embedded slides and sufficient tumor material for DNA isolation [21, 22] . Further details are summarized in Supplementary Table S1 and Supplementary Methods, available at Annals of Oncology online.
MSI assay
DNA was isolated as previously described [23] . In cases with subclonal loss of MMR protein expression, tissue sections were used to microdissect the differentially expressed tumor areas. Tumor MSI status was determined as previously reported (Supplementary Methods, available at Annals of Oncology online) [4] . Tumors initially classified as MSS or MSI-L with concomitant loss of MMR protein expression underwent evaluation of three dinucleotide repeat markers [24] , and reclassified as MSI-H if instability was detected at two dinucleotide markers.
IHC analysis
IHC staining for MLH1, PMS2, MSH2, and MSH6 was performed on all tumors in which MSI status was successfully determined (Supplementary Methods, available at Annals of Oncology online). The slides were evaluated in three categories as retained, loss and subclonal loss of protein expression with stromaland/or lymphocytic cells as internal controls [16] . The cases with subclonal loss of protein expression were re-evaluated to determine the percentage of tumor cells with loss of MMR expression.
Methylation-specific PCR for MLH1
Tumors with loss of MLH1 protein expression underwent testing for hypermethylation status of the MLH1 5 0 regulatory region by methylation-specific PCR, as previously described [25] .
Somatic variant screening
Subject to DNA availability and quality, tumors in which the results of MSI analysis and MMR protein expression were discordant underwent targeted next generation sequencing (NGS) of MMR and POLE genes using the Ion Proton TM System (ThermoFisher, MA) as previously described (Supplementary Methods, available at Annals of Oncology online) [26] . Three additional cases were similarly analyzed using the Ion AmpliSeq Comprehensive Cancer Panel (ThermoFisher) at The Welcome Trust Center for Human Genetics. Frameshift variants in the polycytosine tract in exon 5 of MSH6 were analyzed using Sanger sequencing [27] .
Results
Combined analysis of MMR protein expression and MSI was possible in 696 (81%) ECs (Supplementary Table S1 , available at Annals of Oncology online). The frequencies of MSS, MSI-H and MSI-L were 74%, 24% and 2%, respectively. Among the 516 tumors assessed as MSS, 496 (96%) showed retained expression of all four MMR proteins ( Table 1 Overall, concordance between MSI and IHC analysis was observed in 655 of 696 cases (94%, kappa ¼ 0.854; 95% CI 0.811-0.897, P < 0.001). A PMS2-and MSH6-antibody panel was as effective as the four-antibody panel in detecting MMR protein abnormalities. Twenty-seven concordant cases without MLH1 promoter hypermethylation were identified as potential LS, but the underlying defect was not further tested. Discordant cases (n ¼ 41, 6%) included: subclonal loss of MMR expression (n ¼ 18), MSS or MSI-low cases with loss of MMR expression (n ¼ 20), and MSI-low or MSI-high cases with retained MMR protein expression (n ¼ 3). Details on the sample analysis of discordant cases are shown in Supplementary Figure S1 , available at Annals of Oncology online.
All cases with subclonal loss of MMR protein expression (n ¼ 18) were evaluated in more detail by analyzing MSI in mono-and dinucleotide markers, MLH1 promoter hypermethylation and somatic MMR-and POLE-exonuclease domain (EDM) variants in microdissected tumor areas (Table 2) . Among 16 tumors with subclonal MLH1 and PMS2 loss, 14 had areas of differential expression that were sufficiently large to permit microdissection. Among these, MSI testing of microdissected areas was concordant with IHC analysis in 11 cases; tumor areas with retained MMR expression were MSS, whereas areas with loss of MMR expression showed MSI-H. A further three tumors showed microsatellite stability of markers in microdissected areas regardless of MMR protein expression (cases 13-15, Table 2 ). All 14 cases were found to have somatic promoter hypermethylation of MLH1. One case with subclonal loss of MSH2 and MSH6 protein expression showed microsatellite stability in the differently expressed areas (case 17, Table 2 ). Unfortunately, both cases with subclonal loss of MSH2 and MSH6 protein expression had limited DNA available, and could not be analyzed in more detail.
Analysis of microdissected material from the six MSI-H cases with subclonal loss of MSH6 in addition tocomplete MLH1 and PMS2 protein loss demonstrated frameshift variants in the polycytosine tract of MSH6 in areas with MSH6 loss and stable polycytosine tracts in areas with retained MSH6. Five of these cases displayed MLH1 promoter hypermethylation.
We proceeded to perform detailed analysis of the 23 cases with discordant MSI status and MMR protein expression by examination of dinucleotide markers, MLH1 promoter hypermethylation and/or NGS of the MMR-and POLE genes ( One of 12 cases classified as MSS or MSI-L despite combined loss of MLH1 and PMS2 protein expression, showed mobility shifts in the dinucleotide markers (case 24, Table 3 ). Analysis of the MLH1 promoter was successful in 11 of these cases, and revealed promoter hypermethylation in 10 cases, while the single case lacking MLH1 promoter hypermethylation was found to harbor a pathogenic POLE-EDM variant, p.(P286R).
Of the two MSI-L tumors with solitary PMS2 loss (cases 34-35, Four of five cases classified as MSS/MSI-L with solitary MSH6 loss were informative for further analysis. All four showed microsatellite stable dinucleotide markers. Three tumors carried two (n ¼ 1) or one (n ¼ 2) pathogenic MSH6 variants, while one tumor carried one somatic VUS predicted to affect function by two out of three protein prediction software used (Table 3) . Case 41 with loss of MSH2 and MSH6 protein expression and a MSS phenotype had limited DNA, and was therefore excluded for further analysis.
Discussion
Accurate identification of MMR-deficiency in EC may be important to identify patients with a higher risk of recurrence [3, 4, 28] , and those whose tumors may be a consequence of LS. Similarly to two small studies, we demonstrated high agreement (94%) between MSI and IHC analysis in 696 ECs [13, 14] . Most discordant cases involved loss of MMR protein expression and a MSS/MSI-L phenotype and could be explained by MLH1 promoter hypermethylation or MMR variants. In addition, subclonal loss of MMR protein expression generally corresponded to MLH1 promoter hypermethylation and subclonal MSI within microdissected area of the tumor.
Importantly, the present study demonstrated that <3% of cases displayed subclonal loss of MMR protein expression. The fact that MSI and MLH1 promoter hypermethylation were commonly found in areas with subclonal loss of MLH1 and PMS2 protein expression indicates sporadic intratumor heterogeneity [16, 18, 19] . However, MLH1 germline epimutations cannot be totally excluded [2] . Subclonal loss of MSH6 expression, either in conjunction with or without MSH2 protein expression was also previously observed in EC but the underlying molecular mechanisms remain unclear [12, 20] . In accordance with our findings, subclonal loss of MSH6 in cases with complete loss of MLH1 and PMS2 protein expression has been related to secondary MSI events in MSH6 [20, 29] . Although numbers are limited, subclonal loss of MMR protein expression is not associated with LS. Our data suggest that cases with subclonal loss of MMR protein expression are best classified as MMR-deficient, even though the areas with retained expression are MSS. With regard to MMRdeficiency as a prognostic or predictive marker, it remains to be determined whether subclonal loss of MMR protein expression has the same biological behavior as tumors with MMRproficiency. In view of the limited numbers of cases with subclonal loss of MMR protein expression (3%), (inter)national collaborations are essential to obtain sufficient cases for such an analysis. Pending these future studies, we suggest for uniformity to classify tumors with 10% subclonal loss of MMR protein expression, as being MMR-deficient.
The interpretation of MSI-L cases remains controversial in EC and it is uncertain whether such cases are best considered as MSS or MSI. Similar numbers of DNA slippage events were observed in MSS and MSI-L ECs [30] . To date, no extensive research on the clinical implications of MSI-L in ECs has been performed, and the number of MSI-L cases in our study (n ¼ 11) was too low to permit such an analysis as well. However, most of these showed loss of MMR protein expression and would generally be regarded as abnormal by strategies that rely on IHC alone. Noteworthy, several studies have also shown MSI-L and MSS in association with loss of MMR expression and/or pathogenic germline MMR variants [13, 14, 31] .
Our study shows high agreement between IHC and MSI analysis, but not 100%. Of note, other assessments of DNA defects by IHC analysis, e.g. HER2 gene amplification only reaches 69-98% agreement [32] . Assessment of MMR protein expression is preferred over MSI analysis for the following reasons: lower costs, widely available, and determination of affected MMR gene. Our findings confirm the utility of testing MMR-deficiency using a PMS2-and MSH6-IHC approach [33] , which can be followed by MLH1-and MSH2-IHC in case loss of PMS2 or MSH6 was observed. To overcome suboptimal fixation, drawback of IHC analysis, pathologists can rely on IHC analysis in pre-operative EC specimen [23] . IHC with standard well accepted techniques would appear adequate to identify EC patients with LS and to serve as a biomarker for trials of EC patients harboring MMR-deficiency.
It is debatable whether not screening for germline MMR variants is a limitation of this study. Of note, 5% of all cases in this study can be classified as potential LS (no MLH1 promoter hypermethylation). Somatic screening of the discordant cases did show somatic variants but not in all cases. However, we cannot exclude the possibility of missed large genomic rearrangements within the tested genes, which is a limitation of NGS. Further analysis would improve understanding the molecular basis of the discordant cases, however, this study did not aim to determine the sensitivity and specificity of the two methodologies to identify LS. MSI and IHC analysis are highly concordant therefore germline testing is not needed to conclude which approach is best suitable for identifying patients with LS.
In conclusion, MSI and IHC analysis are highly concordant, also in cases with subclonal loss of MMR expression, therefore, an IHC approach is sufficient for determining MMR-deficiency in EC. Pathologists should be aware of the MMR protein expression patterns, including subclonal loss, to ensure correct classification in daily diagnostic pathology.
